🟢 Telix Pharmaceuticals is trading 8.42% up today after FDA approval of Pixclara for glioma

Telix Pharmaceuticals is trading A$16.99, +8.42% after the U.S. FDA approved Pixclara on September 14, 2026, as the first FDA-approved FET-PET imaging drug for glioma.

• The approval is a major company-specific catalyst and supports expectations for commercial expansion in brain-cancer imaging.
• Telix scheduled investor presentations at the Morgan Stanley Global Healthcare Conference and H.C. Wainwright conference.